Jump to main content.

Dinoseb Quickview (CASRN 88-85-7)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Dinoseb

File First On-Line: 01/31/1987; Last Significant Revision: 08/01/1989

Category (section)
Last Revised
Oral RfD Assessment Yes 01/31/1987
Inhalation RfC Assessment No
Carcinogenicity Assessment Yes 08/01/1989
  • 88-85-7
  • Aatox
  • Aretit
  • Basanite
  • BNP 20
  • BNP 30
  • Butaphene
  • Caldon
  • Chemox General
  • Chemox PE
  • Dibutox
  • more...
Dinoseb Source Documents
Revision History
Date Section Description
04/01/1997 III., IV., V. Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information.
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
Decreased fetal weight LEL : 1 mg/kg-day 1000 1 x10-3 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Reference Concentration for Chronic Inhalation Exposure (RfC)

Not Assessed under the IRIS Program.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • D (Not classifiable as to human carcinogenicity)
  • Weight-of-Evidence Narrative:
    • Dinoseb was not observed to be carcinogenic in two inadequate studies in rats and in mice. In a third study, an increase in benign liver tumors in female mice was not considered to be treatment-related. The increase was much lower in the high dose than the mid dose, there were no decreases in time to tumor, nor any evidence of any of the potentially predisposing lesions in the liver such as hypertrophy, hyperplasia or degeneration which are often associated with known hepatocellular carcinogens.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Not Assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page

Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research

Local Navigation

Jump to main content.